- Report
- September 2026
- 200 Pages
Global
From €7273EUR$7,990USD£6,259GBP
- Report
- September 2026
- 120 Pages
Global
From €7273EUR$7,990USD£6,259GBP
- Report
- July 2026
- 160 Pages
Global
From €4324EUR$4,750USD£3,721GBP
- Report
- July 2026
- 160 Pages
Global
From €4324EUR$4,750USD£3,721GBP
- Report
- July 2026
- 70 Pages
Global
From €4324EUR$4,750USD£3,721GBP
- Report
- July 2026
- 160 Pages
Global
From €3022EUR$3,320USD£2,601GBP
€3778EUR$4,150USD£3,251GBP
- Report
- July 2026
- 160 Pages
Global
From €3022EUR$3,320USD£2,601GBP
€3778EUR$4,150USD£3,251GBP
- Report
- January 2026
- 160 Pages
Global
From €2876EUR$3,160USD£2,476GBP
€3596EUR$3,950USD£3,094GBP
- Report
- August 2026
- 100 Pages
Latin America
From €4324EUR$4,750USD£3,721GBP
- Report
- October 2024
- 200 Pages
Global
From €3413EUR$3,750USD£2,938GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2276EUR$2,500USD£1,958GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2539EUR$2,789USD£2,185GBP
- Report
- June 2025
- 250 Pages
United States
From €2539EUR$2,789USD£2,185GBP
- Report
- June 2025
- 300 Pages
Europe
From €3522EUR$3,869USD£3,031GBP
- Report
- May 2025
- 300 Pages
Global
From €4505EUR$4,949USD£3,877GBP
- Report
- May 2024
- 140 Pages
Global
From €2730EUR$2,999USD£2,349GBP
€3640EUR$3,999USD£3,133GBP
- Report
- August 2026
- 120 Pages
Mexico
From €4324EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
North America
From €4324EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Germany
From €4324EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Italy
From €4324EUR$4,750USD£3,721GBP

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity. It is a long-acting injectable medication that helps to reduce blood sugar levels by increasing insulin production and decreasing glucagon production. It also helps to reduce appetite and promote weight loss. Dulaglutide is approved by the US Food and Drug Administration (FDA) for use in adults with type 2 diabetes and is available in both brand and generic forms.
Dulaglutide is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions such as diabetes, obesity, thyroid disorders, and other endocrine and metabolic disorders. The market is expected to grow due to increasing prevalence of endocrine and metabolic disorders, rising awareness of the importance of early diagnosis and treatment, and the availability of new treatments.
Some companies in the Dulaglutide market include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Show Less Read more